I don’t see any comments in any of the threads about this, following up Dr. KSS’ writings about RLYP. In late October the Hyperkalemia drug Veltassa was approved for sale in the U.S., but with a caveat.
This from the Motley Fool on Oct. 22:
”While FDA approvals usually send a stock soaring higher, investors appear to be spooked by the black-box warning that was included. The warning noted that Veltassa binds to other drugs that are taken orally, which could decrease their absorption and potentially reduce their effectiveness, so the approval stated that no other oral medications should be administered to patients at least 6 hours before or after Veltassa is taken.” The MF article went on to mention that following this news, the RLYP price dropped, then rose 50% in the last week, while the ZSPH stock price (which had dropped a day or so earlier) rose as RLYP fell because of the possible advantage their drug may have, if it does not carry such a warning (Dr. KSS’ concerns about the drug noted).
I am interested in but have not invested in RLYP, just discovering it as I catch up on missed missives. Would like to read other Gummy perspectives on this latest twist.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.